Ashwagandha is often promoted for female fertility, but the verified human evidence does not support the claim that its fertility benefit is already established. Through June 2026, no well-designed clinical trial has shown that Ashwagandha improves ovulation, ovarian reserve, IVF success, clinical pregnancy, or live-birth rates in women. The most defensible conclusion is narrower: standardized root extracts have been studied for stress, thyroid indices, and female sexual function, while fertility-specific claims remain largely preclinical or extrapolated from other populations.
This distinction matters clinically. Reduced stress, better sleep, improved sexual function, or correction of a separately diagnosed thyroid disorder may support general reproductive wellbeing, but none of those outcomes is equivalent to treating infertility. Women trying to conceive should not delay a standard fertility evaluation or replace established treatment with Ashwagandha.
Background: What Ashwagandha Is and Why It Is Discussed in Reproductive Health
Ashwagandha (Withania somnifera (L.) Dunal, family Solanaceae) is an Ayurvedic medicinal plant whose dried mature root is the official drug described in the Ayurvedic Pharmacopoeia of India. The root contains alkaloids and withanolides, a group of naturally occurring steroidal lactones. Modern supplements may contain root, leaf, or combinations of plant parts and may use different extraction processes; products therefore cannot be assumed to be clinically interchangeable.
Several biological pathways make Ashwagandha relevant to reproductive-health research, but biological relevance is not proof of fertility efficacy. Stress physiology can influence menstrual and sexual health, thyroid disorders can affect reproduction, and oxidative stress is studied in ovarian biology. Ashwagandha has human data in some of these adjacent areas, yet direct evidence in infertile women is still missing.
- Stress and cortisol: A 60-day randomized trial in 60 stressed adults found that 240 mg/day of a standardized extract reduced morning cortisol more than placebo. The same study found a reduction in DHEA-S, not an increase, and did not measure ovulation or pregnancy.
- Thyroid indices: A small eight-week trial in adults with subclinical hypothyroidism found significant changes in TSH, T3, and T4 with 600 mg/day of root extract. It was not conducted in women seeking pregnancy and does not establish a fertility treatment.
- Female sexual function: Two small randomized studies used 300 mg of standardized root extract twice daily for eight weeks and reported improvement in questionnaire-based sexual-function outcomes. Neither study measured conception, miscarriage, ovarian reserve, or live birth.
- Preclinical reproductive findings: Reviews describe antioxidant, hormonal, and ovarian effects in animal or laboratory models. Such findings can justify further research but cannot determine a clinical dose or prove benefit in women with infertility.
The Clinical Evidence: What Has Actually Been Measured
The relevant human evidence consists mainly of sexual-function trials, general stress trials that enrolled both sexes, a small thyroid trial, and short-term safety studies.
Direct Fertility Outcomes
No verified randomized trial has tested Ashwagandha as a treatment for female infertility with ovulation, time to pregnancy, clinical pregnancy, IVF response, miscarriage, or live birth as a primary outcome. The NIH National Center for Complementary and Integrative Health states that there is not enough evidence to determine whether Ashwagandha is helpful for female infertility. A 2025 systematic review described possible reproductive-health applications but concluded that more research is needed, while a 2026 review of women’s hormonal modulation emphasized that evidence for PCOS and related applications relies heavily on preclinical studies and extrapolation.
Terms such as “fertility dose,” “IVF protocol,” or “ovarian-reserve treatment” are therefore not evidence-based descriptions for Ashwagandha. They should not be inferred from studies of stress, sexual function, thyroid laboratory values, male infertility, or animal ovaries.
FSH, LH, AMH, and Antral Follicle Count
There is no verified basis for stating that Ashwagandha raises AMH or improves antral follicle count in women with diminished ovarian reserve.
AMH and antral follicle count are useful markers of the remaining follicular pool and expected ovarian response, but they are not direct tests of natural fertility. The American Society for Reproductive Medicine notes that AMH and antral follicle count are sensitive ovarian-reserve markers, while ovarian-reserve results alone do not reliably predict unassisted conception or live birth. Even a genuine change in AMH would require careful interpretation rather than being treated as proof of improved fertility.
Female Sexual Function
A 2015 randomized pilot study evaluated a high-concentration Ashwagandha root extract in 50 women with sexual dysfunction. Participants received 300 mg twice daily for eight weeks. The study reported greater improvements than placebo in total Female Sexual Function Index scores and several domains, but it did not show a statistically significant improvement in the desire domain and did not evaluate fertility.
A separate 2022 randomized placebo-controlled study enrolled 80 otherwise healthy women aged 18 to 50 with sexual dysfunction and no hormonal disturbance. The same schedule—300 mg twice daily for eight weeks—improved sexual-function and sexual-distress scores compared with placebo. Adverse events were comparable between groups. These results may be relevant when sexual dysfunction is itself a treatment target, but they cannot be converted into evidence for ovulation, ovarian reserve, or pregnancy.
Stress, Cortisol, and Reproductive Wellbeing
A randomized double-blind trial in 60 stressed adults used 240 mg/day of a standardized extract for 60 days. Compared with placebo, Ashwagandha produced a greater reduction in morning cortisol and a reduction in DHEA-S; testosterone did not increase in female participants. The study supports a possible stress-modulating effect of that specific extract, but participants were not selected for infertility and reproductive outcomes were not measured.
Stress management can be a worthwhile part of fertility care because infertility itself can be psychologically demanding. However, lowering a stress score or cortisol value should not be presented as evidence that GnRH pulsatility, LH secretion, ovulation, implantation, or live-birth probability has improved. Those links remain hypotheses unless directly tested.
Thyroid Function
It randomized 50 adults with TSH values between 4.5 and 10 μIU/L to 600 mg/day of Ashwagandha root extract or placebo for eight weeks. Four participants withdrew, and the active group showed statistically significant improvement in TSH, T3, and T4 compared with placebo.
This small pilot trial does not justify self-treating subclinical hypothyroidism during fertility care. Thyroid targets before and during pregnancy depend on diagnosis, laboratory methods, thyroid antibodies, medication use, and specialist guidance. Ashwagandha has also been linked to case reports of thyrotoxicosis and may interact with thyroid hormone medicines. Women taking levothyroxine or undergoing fertility treatment should use it only with their clinician’s knowledge and appropriate laboratory monitoring.
PCOS-Specific Evidence
There is currently no verified placebo-controlled human trial showing that Ashwagandha improves menstrual regularity, testosterone, insulin resistance, ovulation, or pregnancy rates in women with PCOS.
A 2026 narrative review discussed plausible effects on stress pathways, metabolic markers, and ovarian function but noted that the evidence base depends heavily on preclinical models and extrapolation from other study populations. Ashwagandha should therefore not be described as a proven PCOS treatment. Evidence-based PCOS care may include lifestyle measures, management of metabolic risk, ovulation-induction medicines, and individualized treatment of symptoms under a qualified clinician.
Preparations: Root Powder, Standardized Extracts, and Brand Claims
The evidence does not support ranking KSM-66, Sensoril, traditional powder, or another branded extract for female fertility. No verified head-to-head trial has compared these preparations for ovulation, AMH, IVF response, pregnancy, or live birth. A label that lists a percentage of withanolides does not establish clinical equivalence because plant part, marker definition, extraction method, dose, and accompanying constituents may differ.
| Preparation | Verified Context | What Can Be Concluded |
|---|---|---|
| Traditional dried root powder | The Ayurvedic Pharmacopoeia of India lists 3–6 g of the drug in powder form. | This is an official traditional dose for the root monograph, not a clinically proven female-fertility dose. |
| Standardized root extract, 300 mg twice daily | Used for eight weeks in small trials of female sexual function and in a short-term safety trial. | The results apply to the studied extracts and outcomes; they do not prove improved fertility. |
| Standardized extract, 240 mg daily | Used for 60 days in a trial of stressed adults. | The trial supports stress and cortisol findings for that extract, not a reproductive protocol. |
| Root extract, 600 mg daily | Used for eight weeks in a pilot trial of adults with subclinical hypothyroidism. | This does not establish use in women trying to conceive or replace thyroid treatment. |
| Root-and-leaf or leaf-containing extracts | Commercially available with phytochemical profiles that may differ from root-only preparations. | They should not be assumed equivalent to the official dried root or to root-only clinical extracts. |
Dosage and Duration: What the Evidence Does Not Permit
There is no validated Ashwagandha dosage schedule for female infertility, diminished ovarian reserve, PCOS-related anovulation, IVF preparation, or prevention of miscarriage. The 300–600 mg/day schedules often quoted online come from studies involving different indications and extracts. Milligrams of extract also cannot be directly converted into grams of traditional powder without validated equivalence data.
| Clinical Question | Verified Evidence | Responsible Interpretation |
|---|---|---|
| Can it increase AMH or lower FSH? | No verified human trial. | Do not promise changes in ovarian-reserve hormones. |
| Can it restore ovulation in PCOS? | No verified human trial. | Do not replace established PCOS evaluation or ovulation-induction treatment. |
| Can it improve IVF response? | No verified trial measuring oocyte yield, embryo outcomes, pregnancy, or live birth. | Disclose all supplements to the fertility clinic and avoid unsupervised use during stimulation. |
| Can it improve sexual function? | Two small eight-week trials used 300 mg twice daily. | Possible short-term benefit for sexual-function symptoms; not evidence of increased fertility. |
| Can it reduce stress? | Small studies exist; one verified trial used 240 mg/day for 60 days. | Stress relief may be a separate therapeutic goal, but fertility benefit remains unproven. |
Classical Ayurvedic Perspective
The Ayurvedic Pharmacopoeia of India defines Ashvagandha as the dried mature root of Withania somnifera. It records tikta and kashaya rasa, laghu guna, ushna virya, and madhura vipaka. Its listed actions include rasayana, balya, vajikarana, and vatakaphapaha. The monograph lists Ashvagandhadyarishta, Ashvagandhadi Leha, and Balashvagandha Lakshadi Taila among important formulations and gives a powder dose of 3–6 g.
These classical descriptors should be presented accurately and without translating them into unproven biomedical outcomes. Vajikarana and rasayana do not by themselves demonstrate increased AMH, normalized gonadotropins, improved oocyte quality, or higher live-birth rates. The official monograph also does not establish a universal combination of Ashwagandha with Shatavari, Kapikacchu, Guduchi, and Amalaki for female infertility.
Classical compound formulations require practitioner-led selection because their ingredients, preparation, indications, and dose are not interchangeable with modern capsules.
Safety During Conception Attempts and Fertility Treatment
Consult a qualified Ayurvedic practitioner and a physician or reproductive endocrinologist before using Ashwagandha while trying to conceive, during fertility treatment, or when taking prescription medicines. Do not use it during pregnancy unless a suitably qualified healthcare professional has specifically advised otherwise.
NCCIH advises avoiding Ashwagandha during pregnancy and breastfeeding. It also cautions that the herb is not recommended for people with autoimmune or thyroid disorders and may interact with thyroid hormone, immunosuppressants, sedatives, anticonvulsants, and medicines for diabetes or high blood pressure. Short-term studies cannot establish safety across months of conception attempts or through early unrecognized pregnancy.
- Pregnancy: Reliable human pregnancy-safety data are lacking, and authoritative guidance recommends avoidance. A clinician should determine when any pre-conception use must stop.
- Thyroid disease: Avoid self-treatment. Monitor TSH and thyroid hormones when a clinician decides use is appropriate, especially with levothyroxine or a history of hyperthyroidism.
- Autoimmune disease: Specialist review is appropriate because authoritative safety guidance recommends caution or avoidance in autoimmune disorders.
- Fertility medicines: Direct interaction studies with gonadotropins, letrozole, clomiphene, progesterone, or IVF protocols are lacking. The clinic should know every supplement being taken.
- Liver and gastrointestinal reactions: Drowsiness, stomach upset, diarrhea, and vomiting can occur. Rare cases of liver injury have been associated with Ashwagandha supplements; stop use and seek medical care for jaundice, dark urine, severe nausea, persistent vomiting, or unusual fatigue.
- Product quality: Prefer products with transparent plant-part identification, extract specifications, batch testing, and contamination screening. A higher declared withanolide percentage should not automatically be interpreted as safer or more effective.
Evidence Gaps and Research Priorities
The central evidence gap is not merely the absence of a perfect study; it is the absence of credible fertility-outcome trials in women. Future research should use authenticated preparations, prospectively registered protocols, adequate sample sizes, and outcomes that matter to patients rather than relying only on surrogate hormones.
- Randomized trials in clearly defined female-infertility populations are needed.
- Studies should report ovulation, time to pregnancy, clinical pregnancy, miscarriage, and live birth.
- PCOS trials should measure menstrual and ovulatory outcomes alongside metabolic and androgen markers.
- Diminished-ovarian-reserve studies should distinguish ovarian response from the probability of pregnancy or live birth.
- Extracts must be characterized by plant part, extraction process, marker compounds, contaminants, and dose.
- Pregnancy exposure, drug interactions, liver safety, and long-term use require stronger surveillance.
- Traditional root powder and classical compound formulations should be studied separately rather than assumed equivalent to branded extracts.
The responsible conclusion through June 2026 is that Ashwagandha has limited human evidence for stress and female sexual-function symptoms, plus a small non-fertility trial in subclinical hypothyroidism. It has not been proven to improve female fertility, PCOS-related ovulation, AMH, FSH, IVF outcomes, pregnancy, or live birth. Any pre-conception use should be individualized, time-limited, disclosed to the fertility team, and based on a separate clinical indication rather than a promise of fertility enhancement.
References
- Ayurvedic Pharmacopoeia of India
- NCCIH
- Effects of Ashwagandha on Reproductive Health: A Systematic Review of Sex-Specific Hormonal and Fertility Outcomes (2025), PubMed
- Withania somnifera in Women’s Hormonal Modulation: A Narrative Review With Implications for Polycystic Ovary Syndrome and Premenstrual Syndrome (2026), PubMed
- An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study (2019), PubMed
- Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial (2018), PubMed
- Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Improving Sexual Function in Women: A Pilot Study (2015), PubMed
- Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract for Improvement of Sexual Health in Healthy Women: A Prospective, Randomized, Placebo-Controlled Study (2022), PubMed
- Safety of Ashwagandha Root Extract: A Randomized, Placebo-Controlled, study in Healthy Volunteers (2021), PubMed
- Unilateral ischemic retinopathy following traumatic intubation mimicking retinopathy of prematurity in a preterm newborn (2020), PubMed
- One year in review 2019: pathogenesis of rheumatoid arthritis (2019), PubMed
- Evaluation of mandibular implant-supported fixed prosthesis retained by 3 dental implants, 1 straight and 2 angled: A retrospective clinical study (2024), PubMed
- ASRM
- ASRM
- Tga (tga.gov.au)
- Ashwagandha as a Unique Cause of Thyrotoxicosis Presenting With Supraventricular Tachycardia (2022), PubMed Central
I was one of those patients who asked which preparation at what dose for which specific situation and got vague answers everywhere I looked. This systematic review is the first source I have found that actually answers the preparation and dose question with specific reference to the trials.
My grandmother used to swear by this and now I understand why. The part about ashwagandha specifically matches what I observed in her health over the years.
The section on timing relative to the cycle was something I hadn’t seen addressed anywhere else. My integrative doctor mentioned Ashwagandha in passing but didn’t say anything about cycle-phase considerations. Is there a standard protocol window that comes up consistently in the trials you reviewed?
The stress-HPA-fertility connection described here explains why so many fertility patients have unexplained infertility. Chronic HPA dysregulation affects every hormone downstream. An adaptogen that genuinely normalizes the stress response would theoretically help a subset of these patients significantly.
I took 300mg KSM-66 daily for 3 months during a fertility treatment cycle. My AMH, which had been declining, held steady. My RE noted it as an unexplained positive finding. I did not disclose the Ashwagandha. I should have, and I will in my next appointment.
I want to understand the proposed mechanism for Ashwagandha improving oocyte quality. The review mentions mitochondrial function and oxidative stress. Is there any clinical evidence beyond animal models for this specific pathway in human oocytes?
My wife’s DHEA-S was low on her fertility workup. Her RE prescribed DHEA supplementation. She has now added Ashwagandha based on this review’s recommendation for adrenal support. Her RE knows and is monitoring. This is what integrated care should look like.
The review mentions that the evidence ‘has moved past debate’ on whether Ashwagandha works for female fertility. I would push back on that characterization. The quality of evidence is still mostly small trials with methodological limitations. Overstating the evidence level can mislead vulnerable patients.
The review makes clear that no human trial has yet shown Ashwagandha improving ovulation or live birth rates in women trying to conceive.
I had secondary infertility for 2 years after my first child. Started Ashwagandha 600mg alongside lifestyle changes. Conceived naturally in month 5. I am not attributing it exclusively to the herb but it was part of a protocol that worked when nothing had for 2 years.
It’s interesting that the authors point out the stress and thyroid studies but those outcomes don’t equal infertility treatment.
What is the maximum safe duration of continuous Ashwagandha use for women trying to conceive? If conception takes 12 months or more, does the protocol recommendation to cycle at 6-on 2-off apply from the start?
Based on the evidence presented I’d hold off on using Ashwagandha as a substitute for standard fertility work up.
My practitioner wants to use fertility alongside ashwagandha. Is this a common combination or is the article’s protocol more commonly used in isolation?
Reading the excerpt I noticed the warning about delaying evaluation that feels prudent.
While the sexual function trials showed modest gains they didn’t measure pregnancy outcomes so the leap to fertility benefit seems premature.
The article stresses that standardized root extracts have data for stress and thyroid yet fertility claims remain preclinical.
I’m curious whether any of the branded extracts like KSM 66 have been tested specifically for ovarian reserve in women.
According to the review the NIH NCCIH says there isn’t enough evidence to decide if Ashwagandha helps female infertility.
It seems the authors want clinicians to keep Ashwagandha separate from proven treatments like ovulation induction drugs.
One takeaway for me is that improving sleep or lowering cortisol alone doesn’t guarantee better chances of conception.
Many online sellers advertise Ashwagandha as a fertility booster but the cited human studies don’t back that claim.
The distinction between general reproductive wellbeing and treating infertility is highlighted as clinically important.
After reading I’ll discuss any supplement use with my reproductive endocrinologist before trying to conceive.
The question of dose and preparation form is exactly what I’ve been struggling to find a clear answer on. Most of what I’ve read either says 300mg or 600mg with no explanation of why, and doesn’t address whether root extract and KSM-66 are interchangeable for fertility specifically. This review is exactly the kind of thing practitioners should be pointing patients to.
for the KSM-66 vs full spectrum question, any Indian sources where you can verify the extract concentration
my husband was skeptical but now he takes it daily. the sleep depth change is hard to argue with
switched from rhodiola to ashwagandha 2 months back after reading about cortisol mechanism. anxiety is way down
The review correctly notes that animal findings can’t dictate a clinical dose for women with infertility.
quick question, the article mentions 300mg vs 600mg dose, does it matter if you split it morning and night or take it all at once 🙏
quick question, the article mentions 300mg vs 600mg dose, does it matter if you split it morning and night or take it all at once
quick question, the article mentions 300mg vs 600mg dose, does it matter if you split it morning and night or take it all at once asked this earlier
where are the control groups in the studies you cite. most ashwagandha RCTs I’ve read have huge placebo effects
ashwagandha saved my marathon training. the recovery time dropped significantly after adding it asked this earlier
my husband was skeptical but now he takes it daily. the sleep depth change is hard to argue with asked this just now
This helped me understand Systematic Review without too much jargon. I would like to know how long to try it before judging results.
@Lisa tried for 6 weeks, 600mg KSM-66, no noticeable effect on my cortisol levels at all. maybe just doesn’t work for everyone
I’m Vata type, the article suggests ashwagandha is better for Vata but doesn’t explain the mechanism clearly
been taking KSM-66 at 600mg before bed for 3 weeks now and my sleep quality has noticeably improved
i’m Vata type, the article suggests ashwagandha is better for Vata but doesnt explain the mechanism clearly
I’m Vata type, the article suggests ashwagandha is better for Vata but doesn’t explain the mechanism clearly asked this last week
unrelated question but has anyone found a good Ayurvedic practitioner in Hyderabad
anyone here combined it with shatavari? wondering if the adaptogenic effects stack or cancel
how long before you see effects on anxiety vs effects on sleep? asking because I want to track which benefit comes first
the rhodiola comparison table was useful. what about eleuthero, that’s the one ive been using
3 months in, the energy stability is real. no jittery crash like with coffee
the part about timing it with ghee vs plain water actually made a difference for me. ghee absorption theory checks out in my experience
quick question, the article mentions 300mg vs 600mg dose, does it matter if you split it morning and night or take it all at once asked this just now
comparing ashwagandha to pharmaceutical anxiolytics is a stretch. the effect sizes in those trials are small
Same here 🙏
tried 5 different brands over 2 years, KSM-66 concentrate is the only one with real effect for me 🙏
how long before you see effects on anxiety vs effects on sleep? asking because I want to track which benefit comes first asked this recently
3 months in, the energy stability is real. no jittery crash like with coffee asked this just now
I came for Systematic Review and this answered the main question. The safety notes could be expanded a little.
for the KSM-66 vs full spectrum question, any Indian sources where you can verify the extract concentration asked this recently
The part about Systematic Review feels realistic. The practical details matter more than people think.
sorry off-topic but does anyone here have experience using Ayurveda for hair loss
💯 my husband was skeptical but now he takes it daily. the sleep depth change is hard to argue with for the Vata types specifically
tried for 6 weeks, 600mg KSM-66, no noticeable effect on my cortisol levels at all. maybe just doesnt work for everyone 🙌
✨ my husband was skeptical but now he takes it daily. the sleep depth change is hard to argue with
I would like more detail on Systematic Review. A few more examples would still help.